Spots Global Cancer Trial Database for secondary
Every month we try and update this database with for secondary cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer | NCT00293540 | Breast Cancer | oophorectomy Tamoxifen | 18 Years - | International Breast Cancer Research Foundation | |
| Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression | NCT02919462 | Carcinoma, Non-... Secondary Advanced Stage ... High Thymidylat... | Oral vinorelbin... Cisplatin Maintenance wit... Pemetrexed Cisplatin Maintenance wit... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients | NCT01420146 | Breast Neoplasm... Secondary HER2 Positive C... | Zr89-trastuzuma... | 18 Years - | Jules Bordet Institute | |
| Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer | NCT00293540 | Breast Cancer | oophorectomy Tamoxifen | 18 Years - | International Breast Cancer Research Foundation | |
| Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan | NCT00507143 | Colorectal Neop... Secondary | irinotecan | 18 Years - | National Cancer Center, Korea | |
| Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer | NCT00293540 | Breast Cancer | oophorectomy Tamoxifen | 18 Years - | International Breast Cancer Research Foundation | |
| Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer | NCT00587145 | Stomach Neoplas... | S-1,Docetaxel | 18 Years - 70 Years | National Cancer Center, Korea | |
| Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression | NCT02919462 | Carcinoma, Non-... Secondary Advanced Stage ... High Thymidylat... | Oral vinorelbin... Cisplatin Maintenance wit... Pemetrexed Cisplatin Maintenance wit... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | NCT01416181 | Secondary Progr... | natalizumab Placebo | 18 Years - 58 Years | Biogen | |
| A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis | NCT01416181 | Secondary Progr... | natalizumab Placebo | 18 Years - 58 Years | Biogen | |
| Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients | NCT01420146 | Breast Neoplasm... Secondary HER2 Positive C... | Zr89-trastuzuma... | 18 Years - | Jules Bordet Institute | |
| Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC | NCT03226236 | Carcinoma, Rena... Vaccination Secondary | boost radiother... Autologous DC v... High-Dose IL-2 | 19 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer | NCT00580359 | Stomach Neoplas... | S-1, capecitabi... | 60 Years - 85 Years | National Cancer Center, Korea | |
| S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer | NCT00580359 | Stomach Neoplas... | S-1, capecitabi... | 60 Years - 85 Years | National Cancer Center, Korea | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | NCT02795988 | Gastrointestina... Adenocarcinoma | IMU-131 Cisplatin and e... | 20 Years - | Imugene Limited | |
| Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer | NCT00506571 | Colorecal Neopl... Secondary | S-1, irinotecan... | 18 Years - | National Cancer Center, Korea | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer | NCT00506571 | Colorecal Neopl... Secondary | S-1, irinotecan... | 18 Years - | National Cancer Center, Korea | |
| Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) | NCT00900627 | Neoplasms Breast Neoplasm... Breast Cancer | AZD8931 Paclitaxel Placebo | 18 Years - 150 Years | AstraZeneca | |
| Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer | NCT01151215 | Neoplasms Breast Neoplasm... Breast Cancer | AZD8931 anastrozole Placebo | 18 Years - | AstraZeneca | |
| A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | NCT00512681 | Stomach Neoplas... | Irinotecan, Oxa... | 18 Years - | National Cancer Center, Korea | |
| A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy | NCT00506207 | Colorectal Neop... Gastric Neoplas... Secondary | S-1, Irinotecan... | 18 Years - | National Cancer Center, Korea | |
| Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan | NCT00507143 | Colorectal Neop... Secondary | irinotecan | 18 Years - | National Cancer Center, Korea | |
| Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC | NCT03226236 | Carcinoma, Rena... Vaccination Secondary | boost radiother... Autologous DC v... High-Dose IL-2 | 19 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer | NCT00506168 | Colorectal Neop... Secondary Drug Therapy, C... | Irinotecan, Cap... | 18 Years - | National Cancer Center, Korea | |
| Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | NCT02716766 | Carcinoma, Hepa... Secondary | Sorafenib Capecitabine Oxaliplatin | 18 Years - 80 Years | The University of Hong Kong |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
